Polycystic Ovarian Syndrome Treatment Market Research
Report 2026: Effect Factors Analysis, Driving Force,
Constraints and Threat Prediction
Polycystic ovary syndrome is reproductive disorder observed during reproductive age of females.
Polycystic ovarian syndrome is depicted by hyperandrogenism, polycystic ovaries and
anovulation. There is no cure for polycystic ovarian syndrome. Medical treatments aim to
manage and reduce the symptoms or consequences of having polycystic ovarian syndrome with
medication for menstrual cycle regulation, infertility treatment, insulin resistance treatment,
weight loss treatment and hyperandrogenism. Polycystic ovarian syndrome occurs both in
normal-weight and overweight women. However, factors such as insulin resistance (IR), type 2
diabetes, obesity, and cardiovascular disease enhances the chances of polycystic ovarian
syndrome occurrence. The factors driving polycystic ovarian syndrome treatment market are
increasing funds and grants for research for novel treatment, increasing product approval and
pipeline candidates, disease prevalence and high prevalence of risk prone population.
Download PDF Brochure Of This Research Report @
https://www.coherentmarketinsights.com/insight/request-pdf/1589
Polycystic Ovarian Syndrome Treatment Market – Driver:
The organic and inorganic strategies by the market players will boost the polycystic ovarian
syndrome treatment market. For instance, in 2016, Millendo Therapeutics, Inc., a
biopharmaceutical company, entered into an exclusive license agreement with AstraZeneca for
the development and commercialization of phase II entered AZD4901, a candidate product for
the treatment of polycystic ovarian syndrome. Moreover, in 2017, Astellas Pharma Inc.
completed its acquisition of Ogeda SA (formerly Euroscreen S.A.). The acquisition will expand
Astellas’ clinical pipeline with fezolinetant, oral compaound for NK3 receptor target.
Fezolinetant was in phase IIa clinical trials for the treatment of menopausal hot flashes,
polycystic ovary syndrome (PCOS) and uterine fibroids. Moreover, product approval by various
approval bodies will expand the treatment option and in turn leading to the market growth. For
instance, in 2014, EffRx Pharmaceuticals SA, got US FDA approval for its proprietary
metformin-based product candidate, EX404, for pediatric polycystic ovary syndrome (PCOS).